Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



From the monthly archives: May, 2017

We are pleased to present below all posts archived in 'May, 2017'. If you still can't find what you are looking for, try using the search box.

BeamLine Diagnostics’ closes a £650k investment round

Beamline Diagnostics, developers of an innovative biopsy triaging system, founded by Dr. Liberty Foreman and Dr. Katherine Willetts, has closed a £650k investment round which was led by a syndicate of Angels in MedCity (AiMC) and other investors.

Read the rest of entry »

Wickham Laboratories Announces Upcoming Webinar on In-Vitro Alternatives

We would like to invite you to our latest webinar, “The Push for In-Vitro Alternatives in Toxicology: Understanding the Process Behind Developing Alternative Safety Testing”, which will take place on 29th June at 3PM London / 10 AM New York.

Read the rest of entry »

Innovate UK launch investment accelerator pilot programme

Innovate UK launch pilot programme in which UK businesses can apply for a share of £8.5m to fund feasibility studies in infrastructure systems or health and life sciences. This pilot programme for Innovate UK provides simultaneous grant funding and venture capital investment for early stage projects led by UK companies. Up to £3m of grant funding and £1.25m of private equity investment is available for projects related to infrastructure systems. This includes ‘smart’ infrastructure, energy, urban living and connected transport. Up to £3m of grant funding and £1.25m of private equity investment is available for projects related to health and life sciences. This includes health, agriculture and biosciences. Innovate UK expect projects to have total costs of up to £150,000. The programme will provide 100% of project costs. Projects should last between 3 and 12 months. The competition is open to single SMEs who are looking for early stage grant fundi ...

Read the rest of entry »

Innovation Forum Leaders Conference 2017

Innovation Forum Leaders Conference 2017 - 'Convergence in Bio-innovation' - 4-5 December 2017, Oxford

The Innovation Forum Leaders Conference 2017 will take place on 4th and 5th December in Oxford, UK and is an invitation only, world-leading conference supporting industry-academic collaborations and investment for early-stage ventures.  Apply for an invitation. Our global conference will bring together over 400 delegates from the healthcare, biotechnology and life science sectors: Academics, start-ups, early stage ventures, SMEs, large pharmaceutical companies, prominent investors and top innovators. CEOs, prominent investors and top innovators will deliver keynote speeches and head discussions on the latest trends in therapeutics, cleantech and medtech as part of our 2-day extensive programme of presentations and workshops. 

 

Exscientia Announces €250 Million Collaboration for a Multiple-Product Development and Licence Option Agreement with Sanofi

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease. Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets* that could work synergistically and be amenable to Exscientia’s powerful bispecific-small-molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets. Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pa ...

Read the rest of entry »

Oxford Endovascular Crowned Winner of ‘Perfect Pitch’ at BioTrinity 2017 in London

OBN, the membership organisation that supports innovative life sciences companies,  today announces that Mike Karim, CEO of Oxford Endovascular is the winner of Perfect Pitch, the fast-paced, interactive and lively pitching session which was a highlight of the BioTrinity 2017 conference programme.  Perfect Pitch involved ten emerging R&D companies pitch in front of a panel of seasoned investors including: Chair: Kate Bingham, Managing Partner, SV Life Sciences (UK)   Maina Bhaman, Director of Healthcare Investment, Touchstone Innovations (UK) Kreske Nickelsen, General Partner & Chief Executive Officer, Joint Polish Investment Fund  (Poland) Graeme Martin, Founder, HatchBox Bioconsulting LLC (US) Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners (UK/France) Andrew McLean, Principal Life Sciences Investor, Oxford Science Innovation (UK) Detlev Mennerich, Director and Investment Manager, Boehringer Ingelheim Ventures (Germany) ...

Read the rest of entry »

Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and Views’.

Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and Views’.  Published quarterly, this newsletter will aim to cover key topics in the biopharmaceutical industry. CREDOS is a specialist consultancy tailored to the discovery and development of biological therapeutics (www.credos-bio.co.uk)

Read the rest of entry »

Scientific program and workshops announced for The Cresset User Group Meeting, 29th – 30th June 2017, Cambridge, UK

Cresset announces full line-up for User Group Meeting.

Read the rest of entry »

Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases

Oxford, UK, 2 May 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection ('CDI'), announces the online publication of results from the Company's Phase 2 clinical trial, called CoDIFy, in The Lancet Infectious Diseases. CoDIFy evaluated the Company's novel antibiotic for the treatment of CDI, ridinilazole, against standard of care, vancomycin. The results showed ridinilazole demonstrated substantial clinical benefit over vancomycin. This included ridinilazole achieving statistical superiority over vancomycin in sustained clinical response ('SCR'), a composite endpoint of cure at the end of treatment and no recurrence 30 days after treatment, a result which was driven by a large numerical reduction in infection recurrence.

Read the rest of entry »

Neuro-Bio Ltd appoints Dr. Robert Haigh as Chief Operating Officer

Oxford, UK; 3rd May 2017 – Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company focusing on neurodegenerative diseases, today announced that it has appointed Dr. Robert Haigh as its new Chief Operating Officer. Dr. Haigh has more than 25 years of senior management and board level experience in pharmaceutical and biotech companies across Europe and the US. He joins Neuro-Bio from KalVista Pharmaceuticals Ltd, a company he co-founded in 2011 and where he served as COO before the company’s recent merger with Carbylan Therapeutics.

Read the rest of entry »

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.

Don't forget about the 'wandering kitchens' near No. 99 on Milton Park on Thursday lunchtime!